Advanced Unresectable Metastatic Melanoma clinical trials

Explore recruiting advanced unresectable metastatic melanoma clinical trials.

Recruiting advanced unresectable metastatic melanoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Unresectable Metastatic Melanoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®

Bulgaria, Italy, Hungary, Lithuania, Germany, Spain +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Advanced Unresectable Metastatic Melanoma trials by city

Advanced Unresectable Metastatic Melanoma clinical trials

Recruiting advanced unresectable metastatic melanoma studies right now

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

A Study of NX-1607 in Adults With Advanced Malignancies

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy

Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma

Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma

A Beta-only IL-2 ImmunoTherapY Study

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Also recruiting in Europe

Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®

Advanced Unresectable Metastatic Melanoma trials by city

Other conditions